Abstract
In years since AZT was first used to treat HIV-infected patients other retroviral drugs have replaced AZT for treating adult patients but it continues to be used for treating at-risk infants and HIV-infected children despite concerns about toxicity. Producing pharmacokinetic information from infants has been limited by limited blood sampling and imprecise and complex quantitative assays. In the Special Feature, Kinai and co-workers at the National Center for Global Health, Tokyo, and Medicine and Keio University School of Medicine, Tokyo, present a new LC-MS/MS method for quantifying AZT-mono, -di and -tri phosphate in blood mononuclear cells
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
